MedTrace Logo

DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer

NCT06690086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1028

Last updated 2024-12-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical validity of the proprietary DermaSensor Elastic Scattering Spectroscopy (ESS) device and classifier algorithm to support assessment of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in the primary care setting.

Conditions

Interventions

PROCEDURE

Lesion biopsy

Lesions enrolled in the study are biopsied to confirm histopathology

DEVICE

DermaSensor Device Use

Users are blinded to the DermaSensor Device result

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • DermaSensor, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen P Merry, MD, MPH · Mayo Clinic

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-17
Primary Completion
2021-12-09
Completion
2021-12-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06690086 on ClinicalTrials.gov